NCT07406633 2026-04-17
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
Phase 2 Recruiting
Clinical Trials
43 trialsNCT05493215 2026-02-17
Imatinib TDM in GIST
University of Kentucky
Phase 2 Recruiting
NCT05152472 2026-01-08
ATEZOGIST
Centre Leon Berard
Phase 2 Recruiting
NCT05385549 2025-08-08
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
Phase 2 Recruiting
NCT01294202 2024-08-02
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT01541709 2024-01-02
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Asan Medical Center
Phase 2 Unknown
NCT00928525 2023-10-05
Basket 1
Italian Sarcoma Group
Phase 2 Completed
NCT05009927 2023-09-01
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Centre Leon Berard
Phase 2 Recruiting
NCT00764595 2023-07-21
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT02365441 2023-07-07
ALT GIST
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT02712112 2023-01-04
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
Phase 2 Completed
NCT04933669 2021-10-12
ZJGIST-01
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT00028002 2020-10-26
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT00278876 2020-01-07
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Asan Medical Center
Phase 2 Completed
NCT00075400 2019-07-24
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00090987 2018-06-06
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
AIDS Malignancy Consortium
Phase 2 Completed
NCT00867113 2018-03-14
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00455559 2018-02-22
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
AEterna Zentaris
Phase 2 Completed
NCT01172548 2017-05-31
INV555
Novartis
Phase 2 Completed
NCT01137916 2017-05-03
Study to Evaluate Imatinib in Desmoid Tumors
Heidelberg University
Phase 2 Completed
NCT00150072 2017-02-23
Efficacy and Safety of Imatinib in Chordoma
Novartis
Phase 2 Completed
NCT00171912 2017-02-23
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Novartis
Phase 2 Completed
NCT00585221 2017-02-10
Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
University of Utah
Phase 2 Terminated
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT01483014 2016-11-18
CONVERT
Novartis
Phase 2 Completed
NCT00030667 2015-04-15
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
National Cancer Institute (NCI)
Phase 2 Completed
NCT01267695 2015-02-03
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Peking University
Phase 2 Completed
NCT00237185 2014-08-19
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Novartis
Phase 2 Completed
NCT00031915 2013-06-19
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00091078 2013-06-05
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00615927 2013-03-15
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Duke University
Phase 2 Completed
NCT00084630 2013-02-28
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025246 2013-02-20
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00354913 2013-01-18
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
Duke University
Phase 2 Completed
NCT00085475 2012-09-24
Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00039364 2012-07-24
Imatinib Mesylate in Treating Patients With Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00237172 2012-05-01
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
Novartis
Phase 2 Completed
NCT00243191 2012-03-29
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00112632 2012-03-08
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Technical University of Munich
Phase 2 Completed
NCT00500188 2011-08-08
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00940563 2011-07-01
A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
Novartis
Phase 2 Completed
NCT00062205 2010-02-09
Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
City of Hope Medical Center
Phase 2 Completed
NCT00290485 2006-04-07
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
Maisonneuve-Rosemont Hospital
Phase 2 Unknown